Dana-Farber Cancer Institute

Our Clinical Partners

Dana-Farber/Brigham and Women’s Cancer Center at Milford Regional Medical Center
Dana-Farber/Brigham and Women’s Cancer Center in clinical affiliation with South Shore Hospital
Dana-Farber Cancer Institute at St. Elizabeth’s Medical Center
Dana-Farber Cancer Institute – Merrimack Valley
Dana-Farber/New Hampshire Oncology-Hematology
Dana-Farber Mammography Services at Whittier Street Health Center

Resources for Referring Physicians

Inpatient Transfer
Physician Gateway
Clinical Trials
Continuing Medical Education

Leadership Team

Clinical Support Services

Zakim Center for Integrative Therapies and Healthy Living
Nutrition Services
Social Work
Survivorship
Adult Survivorship Program
The David B. Perini Jr. Quality of Life Clinic
Stop & Shop Family Pediatric Neuro-Oncology Outcomes Clinic

Pediatric Care Content

Pediatric Care
Pediatric Blood Disorders
Pediatric Brain Tumor Center
Pediatric Cancer Genetic Risk Center
Childhood Hematologic Malignancy Center
Pediatric Imaging
Pediatric Advanced Care Team (PACT)
Psychosocial Care
Childhood Solid Tumor Center
Hematopoietic (Stem) Cell Transplant Program
Pediatric Cancer Survivorship

Gastrointestinal Cancer Center
Genitourinary Oncology
Gynecologic Oncology
Head and Neck Cancer
Hematologic Oncology

Adult Leukemia
Adult Lymphoma
Chronic Lymphocytic Leukemia
Adult Histiocyte Disorders
Multiple Myeloma
Stem Cell Transplantation and Cellular Therapies
Blastic Plasmacytoid Dendritic Cell Neoplasm
Waldenström’s Macroglobulinemia

Imaging
Melanoma
Neuro-Oncology
Non-Malignant Hematology
Oral Medicine and Oral Oncology
Palliative Care
Psychosocial Oncology
Sarcoma
Adult Survivorship
Thoracic Oncology

Pediatric Care

Pediatric Blood Disorders
Pediatric Brain Tumor Center
Pediatric Cancer Genetic Risk Center
Childhood Hematologic Malignancy Center
Pediatric Imaging
Pediatric Advanced Care Team (PACT)
Psychosocial Care
Childhood Solid Tumor Center
Hematopoietic (Stem) Cell Transplant Program
Pediatric Cancer Survivorship

Adult Care Content

Adult Care
Breast Oncology
Center for Cancer Genetics and Prevention
Center for Cancer Therapeutic Innovation
Cutaneous Oncology Program

Adult Survivorship
Thoracic Oncology

Gastrointestinal Cancer Center
Genitourinary Oncology
Gynecologic Oncology
Head and Neck Cancer
Hematologic Oncology

Adult Leukemia
Adult Lymphoma
Chronic Lymphocytic Leukemia
Adult Histiocyte Disorders
Multiple Myeloma
Stem Cell Transplantation and Cellular Therapies
Blastic Plasmacytoid Dendritic Cell Neoplasm
Waldenström’s Macroglobulinemia

Imaging
Melanoma
Neuro-Oncology
Non-Malignant Hematology
Oral Medicine and Oral Oncology
Palliative Care
Psychosocial Oncology
Sarcoma
Adult Survivorship
Thoracic Oncology

Pediatric Care

Pediatric Blood Disorders
Pediatric Brain Tumor Center
Pediatric Cancer Genetic Risk Center
Childhood Hematologic Malignancy Center
Pediatric Imaging
Pediatric Advanced Care Team (PACT)
Psychosocial Care
Childhood Solid Tumor Center
Hematopoietic (Stem) Cell Transplant Program
Pediatric Cancer Survivorship

Adult Care Content

Adult Care
Breast Oncology
Center for Cancer Genetics and Prevention
Center for Cancer Therapeutic Innovation
Cutaneous Oncology Program
For more than 70 years, Dana-Farber Cancer Institute has had one goal: to reduce the suffering caused by cancer through advanced clinical care and scientific research. As a principal teaching affiliate of Harvard Medical School, we are able to attract many of the best and brightest physicians in the world to share in this mission.

At Dana-Farber, we are committed to a multidisciplinary, compassionate, and collaborative model of care that truly puts patients and their families at the center of all that we do. We work in teams organized around combating specific types of cancer, and patients have easy and direct access to the full range of specialists they may need.

Dana-Farber is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), a NCI-designated Comprehensive Cancer Center. DF/HCC harnesses the expertise and resources of Dana-Farber and six other Harvard-affiliated hospitals and research institutions. Dana-Farber is also a founding member of the National Comprehensive Cancer Network, an alliance of the world’s leading cancer centers working together to develop cancer treatment guidelines and research that improve the quality and effectiveness of cancer care.

Dana-Farber is a QOPI® Certified Practice. In addition, the Institute in 2019 was again awarded with “Magnet” status, recognizing its quality patient care, nursing excellence, and innovations in professional nursing practice. This is the fourth consecutive time since 2005 Dana-Farber has earned this designation.

Refer a Patient Online
Refer a Patient by Phone:
   Adult Referrals: 877-441-3324
   Pediatric Referrals: 888-733-4662
Our Clinical Partners

Dana-Farber/Brigham and Women’s Cancer Center brings together specialists from Dana-Farber Cancer Institute and Brigham and Women’s Hospital to treat adults with all types of cancer. Our multidisciplinary teams include medical, radiation, and surgical subspecialists in each type of cancer. We offer the latest treatments, many of which were pioneered here, along with clinical trials of promising new therapies. Dana-Farber/Brigham and Women’s is consistently ranked among the top cancer centers in the nation by U.S. News & World Report and has been the #1 center in New England for 21 years.

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center offers the combined expertise of Dana-Farber Cancer Institute and Boston Children’s Hospital to provide seamless, integrated care for children with all types of cancer and blood disorders – including the rarest and most complex cases. Dana-Farber/Boston Children’s offers more specialists, more treatment options, and more clinical trials than almost any other pediatric center in the world. Dana-Farber/Boston Children’s is consistently ranked among the top institutions for pediatric cancer care by U.S. News & World Report.
Dana-Farber/Brigham and Women’s Cancer Center at Milford Regional Medical Center
20 Prospect Street
Milford, MA 01757

Referrals: 508-488-3700 (medical oncology); 508-488-3800 (radiation oncology)

Dana-Farber/Brigham and Women’s Cancer Center at Milford Regional Medical Center offers the most innovative and advanced cancer care available in a community setting.

The Center is a collaboration between New England’s top cancer center, one of the nation’s best academic medical centers, and a leading community hospital.

The regional care center in Milford provides hematology services, medical and radiation oncology treatment, select Dana-Farber clinical trials, surgical consults, imaging services, and second opinion consults with Dana-Farber subspecialists. In addition, we offer many specialized services, including high-risk screening and genetic counseling, nutrition services, social work, and survivorship care.

Cancer patients at Milford have the full benefit of advances in cancer care and research from Dana-Farber/Brigham and Women’s Cancer Center while enjoying the comfort and convenience of staying in their local community during their treatment.

To speak with a physician liaison about our Milford center, call 617-582-4733.

For more information visit www.dana-farber.org/milford.
Dana-Farber Cancer Institute

Physician Directory

Dana-Farber/Cambridge in clinical affiliation with South Shore Hospital

101 Columbian Street
South Weymouth, MA 02190

Referrals: 781-624-5000

Dana-Farber/Cambridge and Women’s Cancer Center in clinical affiliation with South Shore Hospital, in South Weymouth, MA, provides residents south of Boston with the highest level of cancer care in the region. Experts from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and South Shore Hospital collaborate to offer locally many of the advanced treatments currently offered at Dana-Farber/Cambridge and Women’s Cancer Center in Boston, including clinical trials exploring new therapies. The regional care center in South Weymouth provides imaging, hematology, medical and radiation oncology care. We offer a multidisciplinary surgical oncology program, comprehensive breast care, select Dana-Farber clinical trials, second opinion consults with Dana-Farber subspecialists, high-risk screening and genetic counseling, nutrition services, social work, and survivorship care.

We can provide a smooth transition to Dana-Farber/Cambridge and Women’s Cancer Center in Boston for patients who require care from our physicians with expertise in specific disease areas.

Radiation therapy is also provided at 51 Performance Drive.

To speak with a physician liaison about our South Weymouth location, call 617-582-4733.

For more information visit www.dana-farber.org/southshore.

Dana-Farber Cancer Institute | BRIGHAM AND WOMEN’S HOSPITAL

DANA-FARBER/BRIGHAM AND WOMEN’S CANCER CENTER

in clinical affiliation with South Shore Hospital

OUR TEAM
Dana-Farber Cancer Institute at St. Elizabeth’s Medical Center

736 Cambridge Street
Cushing Pavilion, 5th Floor
Brighton, MA 02135

Referrals: 617-562-7208

Dana-Farber Cancer Institute provides the latest hematology and medical oncology care to patients at St. Elizabeth’s Medical Center. The partnership between Dana-Farber and St. Elizabeth’s enables patients to receive the benefit of Dana-Farber’s advances in care and research at their local hospital. Dana-Farber teams at St. Elizabeth’s and in Boston collaborate to review cases and develop the optimal treatment plan for patients.

Dana-Farber delivers the latest medical oncology care, including chemotherapy, biologic and targeted therapy. Our experienced team also provides care for benign hematologic disorders. Patients also have local access to select Dana-Farber clinical trials exploring new cancer therapies.

Care is closely coordinated with surgical and radiation oncologists at St. Elizabeth’s Medical Center to develop the best possible treatment plan for each patient. Expert imaging, radiation oncology and surgical services from St. Elizabeth’s enable patients to receive comprehensive care in one location.

In addition, a range of clinical and support services is available to help patients and their families through treatment, including genetic counseling, nutrition, social work, spiritual care, and support groups.

For more information visit www.dana-farber.org/stelizabeths.
Dana-Farber Cancer Institute – Merrimack Valley
5 Branch Street
Methuen, MA 01844

Referrals: 978-620-2020

Dana-Farber Cancer Institute — Merrimack Valley provides the latest hematology and medical oncology care to patients in the Merrimack Valley. The center makes it possible to offer the expertise and experience of Dana-Farber, New England’s leading cancer center, while enabling patients to enjoy the comfort and convenience of staying close to home.

Expert hematologist/oncologists, supported by Dana-Farber’s vast clinical resources, offer patients the latest and most advanced treatments for cancer and blood disorders, including access to Dana-Farber’s innovative clinical trials. In addition, a range of clinical and support services is available to patients and their families, reflecting Dana-Farber’s commitment to treating the “whole patient.”

For more information visit www.dana-farber.org/merrimackvalley.
Dana-Farber/New Hampshire Oncology-Hematology provides expert hematology and medical oncology care in Londonderry, NH. The center makes it possible to offer the expertise and experience of Dana-Farber, New England’s leading cancer center, while enabling patients to enjoy the comfort and convenience of staying close to home.

Expert hematologist/oncologists, supported by Dana-Farber's vast clinical resources, offer patients the latest and most advanced treatments for cancer and blood disorders. In addition, a range of clinical and support services is available to patients and their families. Patients may participate in select Dana-Farber clinical trials and meet with Dana-Farber subspecialists for second opinion consults. High-risk screening and genetic counseling, nutrition services, social work, and survivorship care are also offered.

For more information visit [www.dana-farber.org/londonderry](http://www.dana-farber.org/londonderry).
Dana-Farber Mammography Services at Whittier Street Health Center
1290 Tremont Street
Roxbury, MA 02120

Referrals: 617-989-3200 or 617-989-3260

Dana-Farber’s Mammography Suite at Whittier Street Health Center was established in 2013 as a joint effort by Dana-Farber Cancer Institute and Whittier Street Health Center in order to address the structural barriers preventing Boston-area women from being screened for breast cancer.

In the Mammography Suite, a Dana-Farber cancer care team – including skilled, licensed mammography technologists, program coordinators, and breast health educators – provides culturally and linguistically competent care. The goal of the Mammography Suite is to connect low-income, elderly, and medically underserved women to high-quality care facilities and providers.

The Mammography Suite is open Tuesdays through Thursdays, year-round, to provide screening mammograms to eligible patients. For more information, please call the Mammography Suite office at 617-989-3200.

For more information visit our Whittier Street Health Services Mammography Suite webpage.
Resources for Referring Physicians

Inpatient Transfer
We can help with the rapid transfer of patients to our facilities. Our teams will facilitate communication between referring and receiving physicians, locate inpatient beds, and arrange transport.

To transfer adult patients, call MDCONNECT at 877-637-3337 and press “2” for Brigham and Women’s Hospital.
To transfer pediatric patients, call 866-771-KIDS (5437).

Physician Gateway
Our physician portal, Physician Gateway, helps you stay up-to-date on adult patients you have referred to Dana-Farber. Through Physician Gateway, you have access to medical record information related to your patients at Dana-Farber, including consult notes, radiology reports, discharge summaries, test results, medications, allergies, visit history, and a list of care providers. You can also elect to receive email notifications to alert you of important patient activities, such as inpatient and ED admission and discharge events.

Physician Gateway is available for primary care providers, referring providers, and your authorized office staff. To enroll, go to www.physiciangateway.org and follow the link for New Users to create a secure login name and password.

Clinical Trials
Dana-Farber is committed to clinical research that advances the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. Patients at Dana-Farber have access to more than 1,000 clinical trials evaluating new drug, diagnostic, and other treatments in order to bring the latest and most effective therapies from the research bench to patients. In addition, every patient seen in Boston can undergo sequencing of their tumors to identify genetic alterations that may suggest participation in a targeted therapy clinical trial. For more about current trials that may be appropriate for your patients, visit www.dana-farber.org/clinicaltrials.

Continuing Medical Education
Dana-Farber shares advances in cancer research and treatment with the health care community through continuing medical education (CME) courses. To learn about upcoming programs, visit www.dana-farber.org/cme.
Leadership Team

Laurie H. Glimcher, MD — President and Chief Executive Officer
William C. Hahn, MD, PhD — Executive Vice President and Chief Operating Officer; Chair, Executive Committee for Research (ECR)
Scott A. Armstrong, MD, PhD — President, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Chair, Department of Pediatric Oncology
Craig A. Bunnell, MD, MPH, MBA — Chief Medical Officer
Kathleen Burns, MD, PhD — Chair, Department of Oncologic Pathology
Michelle Cox — Senior Vice President for Research Operations
George D. Demetri, MD — Senior Vice President, Experimental Therapeutics
Gerard M. Doherty, MD — Chair of Surgery
Melany Duval — Senior Vice President, Chief Philanthropy Officer
Benjamin Ebert, MD, PhD — Chair, Department of Medical Oncology
Ildemaro Gonzalez — Vice President and Chief Inclusion & Diversity Officer
Anne Gross, PhD, RN, NEA-BC, FAAN — Senior Vice President, Patient Care Services; Chief Nursing Officer
Daphne Haas-Kogan, MD — Chair, Department of Radiation Oncology
Kevin M. Haigis, PhD — Chief Scientific Officer
Bruce E. Johnson, MD — Chief Clinical Research Officer
Jason M. Johnson, PhD — Chief Health Information Officer
Elizabeth A. Liebow — Senior Vice President, Chief Strategy Officer
Maria Megdal — Senior Vice President for Institute Operations
Drew Memmott — Senior Vice President for Cancer Center Administration
Lee M. Nadler, MD — Senior Vice President, Experimental Medicine
Michael L. Reney, MBA — Executive Vice President and Chief Finance and Business Strategy Officer
Barrett J. Rollins, MD, PhD — Linde Family Professor of Medicine, Harvard Medical School
John Ryan — Senior Vice President, General Counsel and Chief Governance Officer
Stephen E. Sallan, MD — Chief of Staff Emeritus
Atul Shinagare, MD — Interim Chair, Department of Imaging
Steven R. Singer, MPA — Senior Vice President and Chief Communications Officer
Robert J. Soiffer, MD — Chair, Executive Committee for Clinical Programs (ECCP)
Lesley Solomon — Senior Vice President and Chief Innovation Officer.
Richard Stone, MD — Chief of Staff
Mary-Ellen Taplin, MD — Chair, Executive Committee for Clinical Research (ECCR)
James Tulsky, MD — Chair, Department of Psychosocial Oncology and Palliative Care
David A. Williams, MD — Associate Chair, Department of Pediatric Oncology
Eric Winer, MD — Chief Clinical Development Officer and Senior Vice President for Medical Affairs
Clinical Support Services

Zakim Center for Integrative Therapies and Healthy Living

The Zakim Center for Integrative Therapies and Healthy Living incorporates the practice of complementary therapies with traditional cancer treatments. Research conducted by Dana-Farber investigators and others has shown that, when used in conjunction with traditional care, integrative therapies can help ease cancer-related symptoms and improve quality of life. The Zakim Center offers a wide range of services, including integrative therapy consults, one-on-one therapies (such as massage and acupuncture), and free group classes (such as qi gong, yoga, mindfulness meditation, and creative arts). Our practitioners have specialized oncology training and are regarded as leaders in the field. For more information, contact 617-632-3322, zakim_center@dfci.harvard.edu.

Nutrition Services

Dana-Farber's registered dietitians have special training in oncology and integrative nutrition. They work with patients to tailor an eating plan that fits with a patient's diagnosis and treatment plan. They also address changes in appetite or weight and help patients use nutrition to manage the side effects of cancer and its treatment. For more information, call 617-632-3006.

Dana-Farber offers several nutrition resources online at www.dana-farber.org/eatingwell.

Social Work

Patients and their loved ones often have many new concerns and anxieties following a cancer diagnosis. Dana-Farber's licensed social workers can help patients and families deal with emotional distress related to a cancer diagnosis, and the impact of cancer on families and loved ones, as well as find supportive resources in their local community. For more information, call 617-632-3301.
Clinical Support Services (continued)

Survivorship

Fortunately, advances in our understanding and treatment of cancer have led to higher rates of survival. At the same time, we have learned that survivors sometimes face myriad medical, social, and emotional issues related to their cancer and its treatment. Dana-Farber is dedicated to providing patients with a continuum of care, taking a balanced and comprehensive approach to research, clinical care, and support for survivors. After patients have completed their treatment and routine follow-up care, they can continue to receive excellent clinical care at one of our three survivorship clinics.

Adult Survivorship Program

The Adult Survivorship Program provides clinical care and services for adult-onset cancer survivors. Through the program, survivors meet with oncologists and nurse practitioners who have expertise in post-treatment and survivorship care. Each patient receives an individualized plan to help them manage possible longterm or late effects of cancer treatment, and maintain a healthy lifestyle. Our services include exercise classes and consultation; sexual health counseling; and consults with cardiologists, endocrinologists, gynecologists, and nephrologists.

For more information about Dana-Farber’s survivorship programs, or to schedule an appointment, call 617-632-4523 or email DFCI_adultsurvivors@dfci.harvard.edu. Learn more at www.dana-farber.org/survivor.

The David B. Perini Jr. Quality of Life Clinic

The David B. Perini Jr. Quality of Life Clinic has been providing multidisciplinary care to childhood cancer survivors since 1993. The clinic is staffed by a team of physicians, nurse practitioners, psychologists, and subspecialty providers who evaluate patients for the long-term and late effects of their cancer therapy. The clinic also has several education and support programs to address the long-term physical and emotional needs of cancer survivors, and to offer tools to live as fully as possible. To learn more, or to make an appointment at the Perini Clinic, call 617-632-5124 or email Perini_Clinic@dfci.harvard.edu. To inquire about conferences, educational programs, and support groups call 800-883-6012 or email Perini_Clinic@dfci.harvard.edu.

Stop & Shop Family Pediatric Neuro-Oncology Outcomes Clinic

The Stop & Shop Family Pediatric Neuro-Oncology Outcomes Clinic addresses the long-term needs of survivors of pediatric brain tumors. Our multidisciplinary clinic allows patients access to our pediatric brain tumor specialists team, which includes neuro-oncologists, neurologists, psychologists, neuropsychiatrists, dermatologists, school liaisons, and other health care professionals with survivorship expertise in a combined clinical setting. Before we see you, our specialists meet to discuss your care and collaborate on our approach to your health. For more information or to schedule an appointment at the Outcomes Clinic, call 617-632-2680 or email empowerclinic@dfci.harvard.edu.
Care for adults with cancer is provided in Boston by Dana-Farber/Brigham and Women’s Cancer Center, ranked #1 in New England for 20 years by *U.S. News and World Report*. Outpatient care takes place at various locations around Dana-Farber’s Longwood and Chestnut Hill campuses, and inpatient care takes place either at Brigham and Women’s Hospital or at Dana-Farber’s Inpatient Hospital located within Brigham and Women’s Hospital. Clinical care is organized around multidisciplinary treatment centers for breast cancer, cutaneous cancer, endocrine cancer, gastrointestinal cancer, genitourinary cancer, gynecological cancer, head and neck cancer, hematologic malignancies, melanoma, neuro-oncology, oral oncology, sarcoma, and thoracic oncology. In each treatment program, patients receive care from specialized cancer physicians, surgeons, radiation oncologists, pathologists, radiologists, nurses, social workers, nutritionists, and other staff. Our team also includes experts in phase 1 clinical trials, cancer genetics and prevention, psychosocial oncology, palliative care, and survivorship care who are available to patients as needed.
Breast Oncology

The Breast Oncology Program at Dana-Farber/Brigham and Women’s Cancer Center provides comprehensive care for patients with all types of breast cancer. Our focused services include programs for:

- Young women with breast cancer
- Older women with breast cancer
- Metastatic breast cancer
- Patients with breast cancer brain metastases
- Inflammatory breast cancer
- Breast cancer during pregnancy
- Breast cancer in men

Experts in the Cancer Genetics and Prevention Program can also create a personalized plan for women at higher risk for developing breast or ovarian cancer.

Patients receive care from a multidisciplinary team of health care professionals with extensive experience and expertise in the unique needs of women with breast cancer.

Clinical research is a vital aspect of our mission at the Breast Oncology Program. We believe that outstanding clinical care is directly linked to an active program of clinical research. Physician-researchers take the questions that arise from their experiences in the clinic, answer them through clinical trials, and take this new knowledge back to the clinic, where it can benefit patients.
Breast Oncology (continued)

All tumors are assessed for molecular markers that guide therapy and help determine eligibility for clinical trials exploring innovative new therapies.

New Patient Appointment Phone: 617-632-2175
Fax: 617-632-3715

Leadership – Breast Oncology

Eric P. Winer, MD, Chief Clinical Development Officer; SVP for Medical Affairs; Chief, Division of Breast Oncology, Breast Cancer Program

Nancy Lin, MD, Associate Chief, Division of Breast Oncology; Director, EMBRACE Metastatic Breast Cancer Program; Director, Program for Patients with Breast Cancer Brain Metastases

Ian Krop, MD, PhD, Associate Chief, Division of Breast Oncology

Caroline C. Block, MD, Clinical Director, Division of Breast Oncology

Tari A. King, MD, FACS, Chief of Breast Surgery, Breast Cancer Program

Ann Partridge, MD, MPH, Vice Chair of Medical Oncology; Director, Program for Young Women with Breast Cancer; Director, Adult Survivorship Program

Jennifer R. Bellon, MD, Director of Breast Radiation Oncology, Breast Cancer Program
Center for Cancer Genetics and Prevention

The Center for Cancer Genetics and Prevention provides genetic testing, counseling, and ongoing clinical management/follow-up for new and established inherited cancer syndromes, including but not limited to: hereditary breast and ovarian cancer; BRCA+ and related genes; Lynch syndrome; familial pancreatic cancer; hereditary colorectal cancer; hereditary paraganglioma-pheochromocytoma syndrome; and Li-Fraumeni syndrome and TP53+ alterations.

Our multidisciplinary team works with patients, family members, and referring physicians to provide cancer risk assessments and develop comprehensive recommendations for managing cancer risk. We are also actively involved in research focused on cancer risk and management.

New Patient Appointment Phone: 617-632-2178
Fax: 617-582-8693

Leadership – Cancer Genetics and Prevention

Judy E. Garber, MD, MPH, Chief, Division of Cancer Genetics and Prevention
Huma Q. Rana, MD, MPH, Clinical Director, Division of Cancer Genetics and Prevention
Sapna Syngal, MD, MPH, Director of Research, Division of Cancer Genetics and Prevention
Center for Cancer Therapeutic Innovation

The Center for Cancer Therapeutic Innovation specializes in conducting clinical trials that evaluate the safety and efficacy of novel therapies for cancer treatment. In this program, disease-focused specialists design and conduct clinical studies that will help understand how new drugs can be safely administered to patients and which types of patients may benefit from specific drugs. This also includes conducting studies of new drug combinations or sequencing of drugs that could maximize the potential effect against cancer. In addition, the center conducts studies exploring the role of new or established therapies across a variety of tumor types. We bring together expertise across a range of tumor types, specialized research nursing and dedicated research staff to help facilitate the care of patients participating in early phase clinical trials.

New Patient Appointment Phone: 617-632-3332
Fax: 617-582-7922

Leadership – Center for Cancer Therapeutic Innovation

Leena Gandhi, MD, PhD, Director
The Cutaneous Oncology Program is dedicated to the treatment and diagnosis of patients with all types of skin cancer, as well as the dermatologic care of cancer patients, including those with graft-versus host disease and skin reactions to anticancer therapies. Our team provides consultation and second opinions, evaluation and management, prevention and early detection counseling, genetic counseling and risk assessment, screening of high-risk individuals, and histopathologic diagnosis and review. The Cutaneous Oncology team also works closely with the Melanoma Treatment Center in the diagnosis and management of melanoma and pigmented lesions at all stages.

Patients are cared for by a multidisciplinary team of specialists and have access to highly specialized therapies, including Mohs and other skin surgeries, targeted, immuno- and chemotherapy, radiation therapy, photo and laser therapies and photopheresis. In addition, patients may have the opportunity to participate in the numerous clinical trials evaluating new treatment options.

Research performed by our faculty is at the cutting edge of oncology, cell biology, and immunology as they relate to skin. Additionally, the program leverages the resources available through the Harvard Skin Disease Research Center, one of six such centers nationally that investigate a variety of skin diseases, including cutaneous oncology.

New Patient Appointment Phone: 617-632-6171
Fax: 617-632-6727

Leadership – Cutaneous Oncology

Thomas S. Kupper, MD, Disease Center Leader
Nicole R. LeBoeuf, MD, MPH, Clinical Director
The Gastrointestinal Cancer Center provides advanced, multidisciplinary care for patients diagnosed with all types of gastrointestinal cancer including esophagus, stomach, small bowel, liver, biliary, gallbladder, pancreas, colon, rectum and anal cancer. We also see patients with neuroendocrine tumors and cancers of unknown primary. Patients are cared for by a multidisciplinary team of specialists who use advanced, innovative techniques to diagnose and treat gastrointestinal malignancies.

Our team is a leader in delivering a tailored, personalized therapy plan that takes each individual patient’s needs into account. We also lead large numbers of clinical trials, providing our patients with the most innovative experimental therapies. Patient treatment is delivered within our specialized centers, where leading-edge research meets world-class patient care. The GI specialized centers include the Center for Esophageal and Gastric Cancer, Colon and Rectal Cancer Center, Pancreas and Biliary Tumor Center, Neuroendocrine and Carcinoid Tumors Program, Liver Cancer Center, and the Young-Onset Colorectal Cancer Center.
Gastrointestinal Cancer Center (continued)

The Gastrointestinal Cancer Center offers genetic counseling and testing to patients with a family history of gastrointestinal cancers and all patients with pancreatic cancer, collaborating with DF/BWCC’s Center for Genetics and Prevention, Center for BRCA and Related Genes, and Lynch Syndrome Center. Our program conducts extensive research to understand the genetic causes of cancer and to evaluate new diagnostic tests for early detection, novel endoscopic techniques, and new medical therapies to prevent gastrointestinal cancers.

New Patient Appointment Phone: 617-632-4500
Fax: 617-582-7875

Leadership – Gastrointestinal Cancer Center

Brian M. Wolpin, MD, MPH, Director
Jennifer Chan, MD, MPH, Clinical Director
The Lank Center for Genitourinary Oncology provides highly-advanced, multidisciplinary care for patients with prostate, bladder, kidney, and testicular cancers. A dedicated team of clinicians specializing in genitourinary cancers – including medical oncologists, urologic surgeons, radiation oncologists, radiologists, pathologists, and other cancer specialists – work together to provide the most effective treatment plan for each patient.

Innovative treatment approaches at the Lank Center include clinical trials of targeted therapies, immunotherapies, and novel combinations; robotic surgery and reconstructive techniques; advanced interventional radiologic techniques; and radiation therapies using real-time image guidance and immobilization and localization techniques. In addition, clinicians and researchers actively collaborate to develop personalized treatment options based on the specific characteristics of each patient’s tumor.

Our team is actively involved in clinical research that will improve our ability to understand and treat genitourinary malignancies. We have multiple active research studies focused on early detection and prevention, assessment of new therapies, quality of life, and the analysis of biological samples to better understand the biology of these diseases.

New Patient Appointment Phone: 617-632-2682
Fax: 617-632-2557

Leadership – Genitourinary Oncology

Toni Choueiri, MD, Director
Bradley McGregor, MD, Clinical Director
Anthony V. D’Amico, MD, PhD, Disease Center Leader, Radiation Oncology
Adam S. Kibel, MD, Disease Center Leader, Urology
Gynecologic Oncology

The Gynecologic Oncology Program cares for patients with suspected or confirmed gynecologic malignancies. Our focused services include programs for:

- Ovarian cancer
- Endometrial/uterine cancer
- Cervical cancer
- Vulvar cancer
- Vaginal cancer
- Gestational trophoblastic disease
- Ovarian Germ Cell Tumors

Our multidisciplinary team members are leaders in gynecologic oncology. The team includes surgeons who were the first in New England to perform robot-assisted radical hysterectomy; medical oncologists who consistently develop novel and targeted therapies; and radiation oncologists who were among the first in the nation to offer 3D image-guided brachytherapy and provide new options that preserve healthy tissue and significantly reduce side effects. All treatment plans are based on a comprehensive diagnosis from pathologists who are exclusively dedicated to gynecologic cancer and make thousands of diagnoses each year. Our physicians are also actively engaged in innovative research designed to bring the latest advances in cancer care to our patients, including clinical trials for even very rare diseases.
Dana-Farber Cancer Institute
Physician Directory

Gynecologic Oncology (continued)

Our care team also includes specialists from the Center for Infertility and Reproductive Surgery at Brigham and Women’s Hospital, one of the premier infertility programs in the country. Patients also have access to sexual health rehabilitation, treatment, and counseling. Advanced genetic tests and counseling are available through Dana-Farber’s Cancer Genetics and Prevention Program.

In addition, experts in Dana-Farber’s new Center for BRCA and Related Genes are dedicated to the prevention of, and novel therapies and research for, BRCA-related cancers, including ovarian cancer.

New Patient Appointment Phone: 617-632-2175
Fax: 617-632-3714

Leadership – Gynecologic Oncology

Ursula A. Matulonis, MD, Chief, Division of Gynecologic Oncology

Joyce F. Liu, MD, MPH, Associate Chief, Division of Gynecologic Oncology; Director of Clinical Research, Gynecologic Oncology

Ross S. Berkowitz, MD, Surgical Director, Gynecologic Oncology

Panagiotis (Panos) A. Konstantinopoulos, MD, PhD, Director of Translational Research, Gynecologic Oncology; Co-Director, Center for BRCA and Related Genes
Head and Neck Cancer

The Head and Neck Cancer Treatment Center at Dana-Farber/Brigham and Women’s Cancer Center is the region’s most comprehensive program dedicated exclusively to patients with head and neck cancers. Specialists evaluate and treat all types and stages of head and neck cancers, from early lesions to rare and challenging cases. Our team has extensive experience in managing the complex treatment required for head and neck cancer patients. The patient’s care team includes specialists from numerous disciplines including head and neck surgery, medical and radiation oncology, pathology, dentistry, oral surgery, reconstructive surgery, nutrition services, social work, speech, voice, and swallowing therapy.

The creation of new and better ways to treat head and neck cancers, and manage the side effects of treatment, is an important focus for the physician-researchers in our program. As a result, patients have access to trials of innovative treatments developed at Dana-Farber as well as at other U.S. medical centers through national collaborative groups.

Our group is a leader in understanding and treating oropharynx cancers caused by HPV. Patients with this type of cancer undergo HPV molecular testing which is the most important marker for prognosis and treatment planning in head and neck cancer. Our clinicians have also developed therapeutic trials to address treatment for patients with HPV related or unrelated tumors, salivary gland tumors, thyroid cancer and cutaneous malignancies.

New Patient Appointment Phone: 617-632-5718
Fax: 617-632-4448

Leadership – Head and Neck Cancer

Robert I. Haddad, MD, Chief, Division of Head and Neck Oncology
Roy B. Tishler, MD, PhD, Director, Head and Neck Radiation Oncology
Ravindra Uppaluri, MD, PhD, Director, Head and Neck Surgical Oncology
Hematologic Oncology

The Center for Hematologic Oncology provides highly-specialized care for adult patients with all types of cancers of the blood, including leukemia, lymphoma, multiple myeloma, and Waldenström’s macroglobulinemia, as well as related disorders of the blood, such as aplastic anemia and myelodysplasia. We collaborate closely with the Division of Stem Cell Transplantation and Cellular Therapies, which is one of the largest and most experienced in the world.

Patients receive world-class care from a full array of specialists including hematologic oncologists, radiation oncologists, hematopathologists, infectious disease specialists, specialized nursing professionals, oncology pharmacists and psychosocial support specialists. This team has deep expertise in each type of blood cancer and develops a personalized treatment plan for each patient, offering the latest therapies and supportive care.

Our center is dedicated to advancing care through innovative research. We offer more than 100 active therapeutic clinical trials through Dana-Farber/Harvard Cancer Center, providing patients with access to the latest therapies.
Hematologic Oncology (continued)

New Appointment Phone:

Adult Leukemia: **617-632-6028**

Older Adult Hematologic Malignancy (OHM): **617-632-6028**

Adult Lymphoma: **617-632-6246**

Chronic Lymphocytic Leukemia: **617-632-6246**

Cellular Therapies: **877-801-2278**

Adult Histiocyte Disorders: **617-632-6246**

Multiple Myeloma: **617-632-3823**

Stem Cell Transplantation: **617-632-6028**

Blastic Plasmacytoid Dendritic Cell Neoplasm: **617-632-6028**

Waldenström’s Macroglobulinemia: **617-632-3823**

Fax (all programs): **617-632-3730**

Leadership – Center for Hematologic Oncology

**Robert J. Soiffer, MD**, Chief, Division of Hematologic Malignancies
Adult Leukemia

The Adult Leukemia Program provides comprehensive care for patients with acute and chronic leukemias and related bone marrow disorders, including myelodysplastic syndromes and myeloproliferative neoplasms. Our team is one of the most experienced in the nation, with a high volume of consultations, patients cared for, and clinical trials offered.

Our program is also dedicated to clinical research that advances the treatment of leukemia. It offers patients a wide array of opportunities to participate in clinical research studies relating to all stages and types of leukemia and related disorders.

Comprehensive services include advanced diagnostics such as molecular and genomic profiling including the Rapid Heme Panel; development of personalized treatment plans; and access to conventional and innovative treatments. Our team collaborates closely with our internationally recognized stem cell transplant and cellular therapies specialists early in the treatment process to optimize outcomes for patients.

New Appointment Phone: 617-632-6028
Fax: 617-632-3730

Leadership – Adult Leukemia

Daniel J. DeAngelo, MD, PhD, Chief, Division of Leukemia
Richard M. Stone, MD, Chief of Staff; Director, Translational Research, Leukemia Program
Eric S. Winer, MD Clinical Director
Adult Lymphoma

The Adult Lymphoma Program offers clinical care from a team of clinicians with highly specialized experience in lymphoid malignancies. Our extensive experience is critical, given the complexity of lymphoma, which exhibits more than 70 tumor types - each requiring a unique approach to treatment. We evaluate more than 1,500 new lymphoma patients each year, including patients with non-Hodgkin and Hodgkin lymphoma as well as rare lymphomas such as mantle cell lymphoma, marginal zone lymphoma, Burkitt lymphoma, and T-cell neoplasms. In addition, our highly specialized Center for Chronic Lymphocytic Leukemia (CLL) provides care for patients with CLL and offers access to clinical trials of exciting new drugs and combinations, as well as extensive prognostic testing, and tissue banking.

We offer new approaches to treatment such as immunotherapy and CART-cell therapy, including many clinical trials of novel immunotherapies. Our team collaborates closely with our internationally recognized stem cell transplant specialists when patients require transplant.

Our team also conducts an active research program to improve outcomes for patients. Our research includes laboratory-based work in lymphoma biology to inform the use of new agents and approaches to interfere with the pathways and abnormalities that drive lymphoma growth and survival. Through our research program, patients have access to clinical trials that are evaluating novel therapies.

New Appointment Phone: 617-632-6246
Fax (all programs): 617-632-3730
Adult Lymphoma (continued)

Leadership – Adult Lymphoma

Philippe Armand, MD, PhD, Chief, Division of Lymphoma
Margaret A. Shipp, MD, Chief, Division of Hematologic Neoplasia; Director, DF/HCC Lymphoma Program
Eric D. Jacobsen, MD, Director, Clinical Operations
Matthew Davids, MD, MMSc, Director, Clinical Research

Chronic Lymphocytic Leukemia

The Center for Chronic Lymphocytic Leukemia provides care for patients with chronic lymphocytic leukemia (CLL), and offers access to clinical trials of exciting new drugs and combinations, as well as extensive prognostic testing, and tissue banking.

As one of only a few dedicated CLL centers in the country, our team of specialists has unique expertise in caring for patients with CLL. We are a centralized hub for CLL research, and our team of laboratory and clinical-based investigators and physicians offers access to clinical trials of new, promising therapies. We are known for our range of clinical trials, which are available for patients with every stage of the disease, from newly diagnosed to refractory disease. We collaborate closely with our Adult Stem Cell Transplantation Program for patients who require transplant.

In our labs, our investigators are studying the biology of CLL, the influence of genetics in CLL, as well as how CLL responds to and may develop resistance to novel therapies. Learn more about the CLL research in the labs of Dr. Jennifer Brown, Dr. Matthew Davids, and Dr. Catherine Wu. You can also hear updates on CLL research and clinical trials from these videos from faculty.

New Appointment Phone: 617-632-6246
Fax: 617-632-3730

Leadership – The Center for Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD, PhD, Director
Adult Histiocyte Disorders

The Adult Histiocyte Disorders Center at Dana-Farber/Brigham and Women's Cancer Center combines world-class patient care with leading-edge research to provide highly effective, personalized treatment options for patients with adult histiocytosis and histiocyte disorders – a group of rare diseases that includes Langerhan's cell histiocytosis, Erdheim-Chester disease, histiocyte sarcoma, Rosai-Dorfman disease, and juvenile xanogranuloma.

One of the first dedicated adult histiocytosis centers in the US, our multidisciplinary team of medical oncologists, pathologists, surgical oncologists, endocrinologists, cardiologists, nephrologists, neurologists, pulmonologists, orthopedists, dermatologists, and other specialists provides the most advanced care for patients.

Our program also leads research to advance the understanding and treatment for this rare set of diseases and improve patient outcomes.

New Appointment Phone: 617-632-6246
Fax: 617-632-3730

Leadership – Histiocyte Disorders Center

Eric D. Jacobsen, MD, Director, Histiocyte Disorders Center
Multiple Myeloma

The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics encompass a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies for multiple myeloma — and we hope the possibility of at least a functional cure in the future. Our program provides comprehensive, state-of-the-art care, including promising new therapies rooted in a bench-to-bedside approach that rapidly translates laboratory discoveries into the clinical setting.

Our program’s comprehensive services include evaluation and diagnosis, consultation and development of personalized treatment plans, and access to both standard of care and also innovative treatments through clinical trials, which are a major focus of our program. Patients also have access to comprehensive supportive services and complementary therapies. We offer exciting new therapeutic combinations, including the next generation IMiDs (specifically the CelMods CC220 and CC480), state-of-the art monoclonal antibody therapies, next generation proteasome inhibitors, histone deactylase inhibitors, novel cytotoxics and immunotherapies (including vaccines), next generation small molecule inhibitors, and cellular therapies such as CAR T, antibody drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs). A key programmatic effort focuses on development of innovative combination strategies to manage toxicity, including peripheral neuropathy and improve quality of life, plus minimize long-term toxicities induced by conventional chemotherapy, as well as identifying the best approaches to induction remission therapy, consolidation, and maintenance. Protocols are offered in the precursor setting (MGUS, smoldering myeloma), for initial therapy, for maintenance and as a salvage in relapsed, refractory disease, as well as in AL amyloidosis.

New Appointment Phone: 617-632-3823
Fax: 617-632-3730

Leadership – Multiple Myeloma

Kenneth C. Anderson, MD, Program Director
Paul G. Richardson, MD, Clinical Program Leader and Director of Clinical Research
Jacob Laubach, MD, Clinical Director
Nikhil C. Munshi, MD, Director of Basic and Correlative Science
Stem Cell Transplantation and Cellular Therapies

The Division of Stem Cell Transplantation and Cellular Therapies has been a leader in cellular therapies since our program’s founding in 1972. Our stem cell transplantation program is one of the largest and most experienced centers in the world. We have performed more than 10,000 transplants for adult patients.

Our program is also at the forefront of emerging cellular therapies such as CAR T-cell therapy. We are the highest volume center in New England, offering all commercial CAR T products. Many types of cellular therapy are being explored in clinical trials such as CAR T cells, genetically and non-genetically-modified T cells, NK cells, and vaccines.

Our transplant and cellular therapies experts work collaboratively to determine the best treatment approach for patients. Our team includes specialized care from experts in infectious disease, neurology, gynecology, oral medicine, dermatology, and more as needed. We also offer financial counseling, social work, nutrition, and survivorship care throughout a patient’s treatment journey.

The Connell and O’Reilly Families Cell Manipulation Facility (CMCF) is a key part of our transplant and cellular therapies program. The CMCF processes cells for more than 600 stem cell transplants each year and is focused on developing new cell manufacturing procedures and providing cellular products for patients enrolled in phase 1 and 2 clinical trials. The lab currently supports more than 40 diverse active clinical research protocols, with a focus on translational research in stem cell transplantation and immune therapy for cancer. The CMCF recently tripled its capacity to address the growing cellular therapy field.
Stem Cell Transplantation and Cellular Therapies (continued)

New Appointment Phone: 617-632-6028
Fax: 617-632-3730

Leadership – Division of Stem Cell Transplantation and Cellular Therapies

Robert J. Soiffer, MD, Co-Chief, Division of Stem Cell Transplantation and Cellular Therapies; Chief, Division of Hematologic Malignancies

Catherine J. Wu, MD, Chief, Division of Stem Cell Transplantation and Cellular Therapies

Joseph H. Antin, MD, Chief, Stem Cell Transplantation, Emeritus

Corey Cutler, MD, MPH, FRCPC, Medical Director, Stem Cell Transplantation Program

Vincent Ho, MD, Director of Clinical Operations, Stem Cell Transplantation Program

Caron Jacobson, MD, Medical Director, Immune Effector Cell Therapy Program

John Koreth, MBBS, DPhil, Director of Translational Research, Stem Cell Transplantation Program

Sarah Nikiforow, MD, PhD, Technical Director, Immune Effector Cell Therapy Program; Associate Medical Director, Connell and O’Reilly Families Cell Manipulation Core Facility

Jerome Ritz, MD, Executive Director, Connell and O’Reilly Families Cell Manipulation Core Facility

Rizwan Romee, MD, Director of Haploidentical Donor Transplant Program
Blastic Plasmacytoid Dendritic Cell Neoplasm

The Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Center at Dana-Farber/Brigham and Women’s Cancer Center combines world-class patient care with leading-edge research to provide highly effective, personalized treatment options for patients. BPDCN is a rare and aggressive hematologic malignancy that affects fewer than 1,000 people each year. Our center is one of the first in the U.S. to focus on care and research for patients with BPDCN.

Because BPDCN can affect the bone marrow, blood, lymph nodes, and skin, patient care involves a multidisciplinary team. From pathologists involved in diagnosis to oncologists and dermatologists who lead the treatment team, our experts use novel approaches to the evaluation, diagnosis, and treatment of patients with BPDCN.

Our team is also actively involved in basic and clinical research to better understand BPDCN and improve outcomes.

New Appointment Phone: 617-632-6028
Fax: 617-632-3730

Leadership – Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Center

Andrew Lane, MD, PhD, Director
Waldenström’s Macroglobulinemia

The Bing Center for Waldenström’s Macroglobulinemia (WM) provides comprehensive, state-of-the-art care – including promising and innovative non-chemotherapy targeted agents through clinical trials that are focused on patients with Waldenström’s Macroglobulinemia and related IgM disorders. Since its establishment in 1999, the Bing Center has seen over 2,500 repeating patients, with 30,000 patient visits, making it the largest referral center for this disease.

The Bing Center is the largest research center in the world devoted to the basic, translational, and new drug development studies for Waldenström’s, and was responsible for the discovery of the genomic basis for Waldenström’s, and approval of ibrutinib as the first therapeutic for Waldenström’s by the FDA and EMA. We have led efforts to define the incidence and clinicopathological characteristics of the familial form of Waldenström’s Macroglobulinemia, which affects approximately 20 percent of all patients. By establishing a family registry, which has recruited over 1,500 patients and their family members, our program has also gained important insights into the genetic basis of this disease.

New Appointment Phone: 617-632-3823
Fax: 617-632-3730 or 617-632-4862

Leadership – Waldenström’s Macroglobulinemia

Steven P. Treon, MD, PhD, Director, Bing Center for Waldenström’s Macroglobulinemia
Jorge J. Castillo, MD, Clinical Director, Bing Center for Waldenström’s Macroglobulinemia

OUR TEAM
The Department of Imaging offers a complete range of diagnostic examinations using state-of-the-art, fully accredited imaging equipment, as well as various therapies using various radioisotopes. The members of the imaging team are multimodality and whole body imaging experts in cancer imaging who focus on specialized consultative and interpretive cancer imaging services, individualized patient care, and optimal communication with our clinical providers. Our radiologists, technologists, nurses and staff are committed to provide high quality, personalized, and compassionate care to our patients while maintaining the highest safety and quality standards, and to enable translational cancer research and drug development through the use of imaging.

New Patient Appointment Phone: 617-632-4444

Leadership – Department of Imaging

Atul B. Shinagare, MD, Interim Chair, Department of Imaging
Fadi El-Merhi, MD, Clinical Director, Ultrasound
Heather Jacene, MD, Clinical Director, Nuclear Medicine and Theranostics
Jyothi Jagannathan, MD, Clinical Director, MRI
Katherine Krajewski, MD, Clinical Director, Diagnostic Radiology and CT
Melanoma

The Melanoma Treatment Center offers highly specialized care for patients with all forms of melanoma. Our team of medical, dermatologic, surgical and radiation oncologists, dermatopathologists, and radiologists are experts who focus specifically on treating melanoma. The center conducts weekly multidisciplinary clinics where specialists from all disciplines discuss patient cases and develop the most effective treatment plan for each individual patient.

Our active clinical research program offers, on average, 14 clinical trials for high-risk patients and those with advanced disease. Innovative therapies being evaluated through clinical trials include immunotherapies, antiangiogenesis treatment, and targeted therapies.

New Patient Appointment Phone: 617-632-6869
Established Patient Appointment Phone: 617-632-5055
Fax: 617-632-6727

Leadership – Melanoma

F. Stephen Hodi, Jr., MD, Director
Martin C. Mihm, Jr., MD, Associate Director
Patrick Ott, MD, PhD, Clinical Director
The Center for Neuro-Oncology provides expert care for patients with primary and metastatic brain tumors, spinal cord cancer, and neurologic complications from cancer and its treatment. Care is coordinated by a team of clinicians specializing in neuro-oncology, neurosurgery, radiation oncology, psychosocial oncology, nursing, neuropathology, neuropsychology, social work, and genetic counseling. Through our multidisciplinary clinic, patients have the benefit of meeting with our team of surgical, medical, and radiation oncologists at one time and in one place to develop individualized treatment plans.

Clinical care is supported by a strong clinical and basic science research program. The clinical research program is a leader in neuro-oncology clinical trials, including immunotherapy, targeted therapies and inhibitors of angiogenesis. In addition, by routinely testing patients with glioblastoma and anaplastic gliomas for common mutations, we are able to tailor treatment plans for patients. The basic science program aims to enhance the understanding of neurologic cancers, including why tumors develop in the brain, and the mechanisms that drive tumor growth and resistance to therapy. Our investigators also collaborate with the North American Brain Tumor Consortium, National Cancer Institute, and pharmaceutical companies to develop new approaches to the treatment of brain and spinal cord tumors.
Neuro-Oncology (continued)
New Patient Appointment Phone: 617-632-3703
Fax: 617-632-4773

Leadership – Neuro-Oncology
Patrick Y. Wen, MD, Director
David Reardon, MD, Clinical Director
Brian M. Alexander, MD, MPH, Disease Center Leader, Radiation Oncology
Ennio A. Chiocca, MD, PhD, Disease Center Leader, Neurosurgery
Eudocia Q. Lee, MD, MPH, Director of Clinical Research, Neuro-Oncology
Lakshmi Nayak, MD, Director, Center for CNS Lymphoma
Non-Malignant Hematology

The Non-Malignant Hematology Treatment Center offers comprehensive care for all types of hematologic disorders. The team includes hematologists, hematopathologists, specialists in transfusion medicine, specialists in nuclear medicine, and nurse practitioners with a specific focus on hematologic disorders. The Hematology Division is also focused on both basic and clinical research. We offer patients the opportunity to participate in clinical trials for sickle cell disease, hemophilia, ITP, blood clots, as well as other disorders.

New Patient Appointment Phone: 617-732-6089
Fax: 617-732-5706

Leadership – Non-Malignant Hematology

Nancy Berliner, MD, Division Chief
Maureen M. Achebe, MD, MPH, Clinical Director

Oral Medicine and Oral Oncology

The Oral Medicine and Oral Oncology service at Dana-Farber/Brigham and Women's Cancer Center provides comprehensive oral health care services for cancer patients and cancer survivors. Our oral medicine experts will work closely with your patient and their care team to help them maintain optimal oral health, and minimize the risk of developing oral problems. The Oral Medicine and Oral Oncology clinical team is available before, during, and after cancer treatment to ensure that your patient remains healthy and comfortable throughout treatment and beyond.

New Patient Appointment Phone: 617-632-4804
Fax: 617-632-4448

Leadership – Oral Medicine and Oral Oncology

Nathaniel Simon Treister, DMD, DMSc, Clinical Director
Palliative care provides patients relief from the symptoms, pain, and stress of a serious illness. The goal is to improve quality of life for both the patient and the family by caring for the body, mind, and spirit. A team of physicians, nurse practitioners, physician assistants, social workers, pharmacists, and chaplains, all with specialized training and experience in palliative medicine, work together with a patient’s other doctors to provide an extra layer of support.

Palliative care is appropriate at any age and at any stage in a serious illness and can be offered along with curative treatment. We offer outpatient consultation for patients with cancer and other diagnoses. In addition, our Inpatient Palliative Care Unit team cares for oncology patients with high symptom management needs.

Leadership – Adult Palliative Care

James Tulsky, MD, Chair, Department of Psychosocial Oncology and Palliative Care

Psychosocial Oncology

The Psychosocial Oncology Program is dedicated to helping patients cope with cancer, and make it through treatment. Our team works closely with oncology teams to seamlessly manage health and existential anxieties; chronic mental health issues; physical symptoms with psychological dimensions; and psychological symptoms and side-effects that, left unchecked, might compromise the integrity of cancer care. To do this, we offer an array of services, including mental health evaluation, individual psychotherapy, group counseling, and medication management. We also have several specialized offerings including a menopausal symptom clinic, a sexual health program, and a mental health healing program for young adults with cancer.

Leadership – Adult Psychosocial Oncology

James Tulsky, MD, Chair, Department of Psychosocial Oncology and Palliative Care

Ilana M. Braun, MD, Chief, Division of Adult Psychosocial Oncology
The Sarcoma Center provides expert multidisciplinary evaluation and treatment for patients with bone and soft tissue tumors including gastrointestinal stromal tumor (GIST), desmoid fibromatosis, and nearly 200 other kinds of connective tissue neoplasms. Because treatment may include a combination of surgery, targeted therapy, chemotherapy and radiation therapy, complex care is coordinated among a team of health care professionals that includes medical, surgical, radiation and orthopedic oncologists as well as sarcoma-specific pathologists and radiologists, psychosocial experts skilled in sarcoma care, as well as other specialists as needed.

Members of the sarcoma program are at the forefront of developing advanced medical, surgical, and radiation therapies, and diagnostic tools and techniques. For example, medical oncologists at the center pioneered the research that changed the standard of care for patients with GIST, as well as other sarcomas including leiomyosarcomas, liposarcomas and epithelioid sarcoma. The team continues to actively research advanced and targeted therapies to reduce recurrence rates and improve patient outcomes. We also use advanced molecular diagnostics (such as tumor DNA mutation analysis and other genotyping tools), as per best emerging practice, to diagnose and develop treatment plans for patients.

New Patient Appointment Phone: 617-632-5122
Fax: 617-632-3408

Leadership – Sarcoma

George D. Demetri, MD, FACP, FASCO  Director and Disease Center Leader, Medical Oncology
Suzanne George, MD,  Director of Clinical Research
Priscilla Merriam, MD,  Clinical Director
Elizabeth H. Baldini, MD, MPH,  Director, Radiation Oncology
Christopher D.M. Fletcher, MD, FRCPath,  Director, Surgical Pathology
Chandrajit P. Raut, MD,  Director, Surgical Oncology
John E. Ready, MD,  Director, Orthopaedic Oncology
Adult Survivorship

The Adult Survivorship Program provides high quality clinical care and services for DFCI patients who have completed their cancer treatment. Through the program, survivors can meet with a care team that includes survivorship-focused nurse practitioners, as well as a wide array of physician specialists who are available to treat late and long-term effects of cancer treatment. Each patient receives a comprehensive Treatment Summary and Survivorship Care Plan to provide them with guidance on follow-up care and surveillance, manage any effects from their treatments and to develop and maintain a healthy lifestyle.

Our specialized services include a sexual health program, support for insomnia, and oncofertility and tobacco cessation counseling programs. In addition, oncology-focused cardiologists, endocrinologists, gynecologists, and nephrologists are available for consultation as part of our comprehensive survivorship care. We offer an ongoing survivorship virtual patient education series, as well as innovative resources and research to help adult survivors find solutions to problems they may face after cancer treatment.

New Patient Appointment Phone: 617-632-4523
Fax: 617-632-6807

Leadership – Adult Survivorship

Ann H. Partridge, MD, MPH, Director
Thoracic Oncology

The Lowe Center for Thoracic Oncology provides expert care for patients with non-small cell and small cell lung cancer, malignant mesothelioma, mediastinal and thymic tumors, and metastatic cancers to the chest. Because many patients require therapy that may include a combination of chemotherapy, immunotherapy, targeted therapy, radiation, and surgery, care is coordinated among a multidisciplinary team. We routinely perform comprehensive genomic testing of tumors from all patients with advanced non-small cell lung cancer using the latest next generation sequencing methods to evaluate for changes in over 400 genes. We offer a wide variety of therapeutic approaches and clinical trials of novel therapies based on the genomic and immunologic makeup of the individual patient’s cancer.

In addition to providing superior standard treatment options, the thoracic oncology team is involved in clinical and laboratory research to identify innovative treatment strategies for thoracic malignancies. These include molecular targeted therapies, based on genomic analysis of tumors, and immune therapies. Our physicians are also leaders in national cooperative group studies through the Alliance for Clinical Trials in Oncology. As a result of this cutting-edge research, most patients will be offered the opportunity to participate in a clinical trial as one of their treatment options.

New Patient Appointment Phone: 617-632-6875
Fax: 617-632-4413

Leadership – Thoracic Oncology

Pasi A. Jänne, MD, PhD, Thoracic Oncology Division Chief
Mark M. Awad, MD, PhD, Clinical Director
Scott J. Swanson, MD, Disease Center Leader, Surgical Oncology
Raymond H. Mak, MD, Disease Center Leader, Radiation Oncology
Pediatric Care

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center represents the integrated pediatric oncology and hematology program at Dana-Farber Cancer Institute and Boston Children’s Hospital. We deliver compassionate, comprehensive care to children with, and survivors of, all types of childhood cancers and related conditions. Our patients benefit from a multidisciplinary team of physicians who specialize in treating children and adolescents with cancer and blood disorders. Each patient has a primary care team that includes a pediatric hematologist, oncologist or neuro-oncologist, as well as pediatric oncology nurses and nurse practitioners. Subspecialties including surgeons, neurosurgeons, radiation oncologists, cardiologists, gastroenterologists, and endocrinologists also provide care. Psychological and emotional support is provided by psychologists, child life specialists, and clinical social workers. The spectrum and depth of care we provide, from diagnosis to survivorship, is unparalleled.

Our pediatric cancer specialists are organized across five program areas including: Blood Disorders, Brain Tumors, Hematologic Malignancies, Solid Tumor and Stem Cell Transplant. Providers in Palliative Care, Psychosocial Oncology, Cancer Risk, and Survivorship are also integral to the care of our pediatric patients. We are eager to work with you to provide the best possible care for your young patients.
The New Patient Coordinator will arrange an appointment based on your patient’s needs. They will:

• Connect you with the appropriate specialist
• Identify which of your patient’s clinical materials to send in advance for our clinicians to review, such as imaging, lab results or pathology
• Call your patient’s family and schedule the appointment

After your patient’s visit, you will receive an update about their diagnosis and treatment plan.

For after-hour and emergency referrals, call our 24-hour page service at 617-632-3352. Ask for the pediatric oncology consult physician or the pediatric hematologist/oncologist on call.

**International Referrals**

Please contact the Dana-Farber/Boston Children’s international new patient coordinator by calling 01-617-632-2952 or emailing pedi_international@dfci.harvard.edu. The new patient coordinator will facilitate the medical review of patient records and appointment scheduling as well as provide assistance with customs and immigration, transportation, and hotel and housing accommodations.
Pediatric Blood Disorders

Our Pediatric Blood Disorders team is internationally known for its wide range of clinical, research, teaching, and laboratory services. We have special expertise treating patients and families with all forms of non-malignant blood disorders, including anemias (including sickle cell, thalassemias, enzyme deficiencies, and membrane disorders), bone marrow failure syndromes, blood clots (thrombosis), autoimmune blood disorders (including immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evans syndrome), and white blood cell disorders. Our team provides the pediatric services for the Boston Hemophilia Center, a federally funded joint program with Brigham and Women’s Hospital for the comprehensive care of children with bleeding disorders (including hemophilia, von Willebrand disease and platelet disorders).

Patients receive care from a team of pediatric hematologists, nurses, nurse practitioners, social workers, and physician assistants. Multidisciplinary team members also commonly include hematopathologists, transfusion medicine, surgeons, immunologists, and other specialists. As a group, we develop individualized care plans that meet the medical, physical, emotional, and informational needs of our patients and families. We believe families and referring physicians are especially important in the long-term health management plans of children with blood disorders, and we involve them in all treatment decisions.

Our CAP/CLIA-certified clinical laboratory and pathology services deliver the highest quality results. With our oncology colleagues, we offer access to New England’s most successful and advanced pediatric stem cell transplantation program. Through our Gene Therapy Program we now can offer curative options for sickle cell disease, thalassemia, hemophilia and Wiskott-Aldrich Syndrome.
**Pediatric Blood Disorders** (continued)

Our basic science and clinical researchers are recognized for their contributions to improving the understanding and treatment of pediatric blood disorders. Our discoveries frequently lead to new clinical treatments that minimize the impact of these often life-long conditions.

New Patient Appointment Phone: **617-355-8246, x 1**

Fax: **617-730-0641**

**Leadership – Pediatric Blood Disorders Center**

**Matthew Heeney, MD**, Clinical Director, Blood Disorders Center
Pediatric Brain Tumor Center

Our Pediatric Brain Tumor Center is the largest pediatric neuro-oncology program in New England and is globally recognized for its expertise in treating children and young adults with brain and spinal cord tumors. The Neuro-Oncology Program brings together a multi-disciplinary team of pediatric neuro-oncologists, neurosurgeons, radiation oncologists, neurologists, neuroradiologists, and neuropathologists, among other specialists at Dana-Farber Cancer Institute and Boston Children’s Hospital, who are entirely devoted to treating young patients with brain and spinal cord tumors. Our clinical team provides comprehensive coordinated care and treatments across these disciplines while ensuring the highest possible functional and quality of life for every patient and their families.

As one of the leading research centers for the study of pediatric central nervous system tumors, our program offers access to advanced technologies such as the Intraoperative MRI, as well as unique treatment options through our extensive clinical trials program. We are members of the Pacific Pediatric Neuro-Oncology Consortium (PNOC), Pediatric Brain Tumor Consortium (PBTC) and Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT) consortium. These national and international affiliations, as well as our internally-initiated clinical trials, enable us to offer many treatments unavailable at other institutions.

For survivors of all ages, we provide specialized care through the Stop & Shop Family Pediatric Neuro-Oncology Outcomes Clinic, which is dedicated to survivors of brain and spinal tumors, addressing late-effects caused by their tumors and their treatments (physical, psychological, social, and intellectual challenges) and empowers children and young adults to thrive in their communities.
Pediatric Brain Tumor Center (continued)

New Patient Appointment Phone: 617-632-2680 or 888-733-4662
Fax: 617-632-4897
Email: pedibraintumor@dfci.harvard.edu

Leadership – Pediatric Brain Tumor Center
Katherine E. Warren, MD, Clinical Director, Pediatric Neuro-Oncology
Pediatric Cancer Genetic Risk Program

The Pediatric Cancer Genetic Risk Program at Dana-Farber/Boston Children’s provides multidisciplinary, consultative care to patients and their families whose condition or family history suggests an inherited risk of cancer. We provide cancer risk assessment, comprehensive recommendations for managing cancer risk, and psychosocial support for families affected by hereditary cancer. We also conduct research into many aspects of cancer risk and its management.

Our program includes expert pediatric oncologists, genetic counselors, psychologists, and other specialists at both Dana-Farber Cancer Institute and Boston Children’s Hospital. A visit to our program usually includes time with both a physician and a genetic counselor, both of whom have expertise in all forms of inherited cancer syndromes that affect children. Specialized psychosocial consultation to discuss the family impact of genetic testing and hereditary cancer is also offered to each family.

New Patient Appointment Phone: 617-632-4298
Fax: 617-394-2699
Email: pedi_genetics@dfci.harvard.edu

Leadership – Pediatric Cancer Genetic Risk Program
Lisa Diller, MD
Junne Kamihara, MD, PhD
Pediatric Imaging

Diagnostic imaging services for our pediatric patients are provided by Boston Children’s Hospital Department of Radiology. Services include CT/CAT scan, MRI, nuclear medicine (including PET), diagnostic X-rays, and ultrasound. Boston Children’s Hospital has state-of-the-art PET/CT and SPECT/CT scanners dedicated exclusively for pediatric use, and is the first pediatric hospital to have an Intraoperative MRI — an operating room with a mobile MRI unit to provide imaging before, during, and after surgery, resulting in better precision and safety.

Call 888-PEDI-ONC/888-733-4662 to schedule an imaging appointment for a pediatric patient.
Childhood Hematologic Malignancy Center

The Childhood Hematologic Malignancy Center at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center is one of the top pediatric leukemia and lymphoma treatment centers in the world. The hematologic malignancies team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center is recognized for its expertise in treating leukemia and lymphoma (including Hodgkin and non-Hodgkin lymphoma), diseases that comprise approximately one-third of all childhood cancer cases. Our physicians head the Dana-Farber Cancer Institute ALL Consortium, an international organization focused on acute lymphoblastic leukemia (ALL) treatment and research. Our treatment results for children with newly-diagnosed ALL are among the best published cure rates.

New Patient Appointment Phone: 617-632-5508 or 888-733-4662
Fax: 617-582-7434
Email: pedi_onc@dfci.harvard.edu

Leadership – Pediatric Hematologic Malignancies Center

Andrew E. Place, MD, PhD, Co-Director, Hematologic Malignancies Center
Kimberly Stegmaier, MD, Co-Director, Hematologic Malignancies Center
Pediatric Advanced Care Team (PACT)

The Pediatric Advanced Care Team (PACT) supports families and children with serious illnesses with palliative care that prevents, reduces, and soothes symptoms. PACT physicians work with the primary health care team to treat the underlying illness, while at the same time, striving for optimal quality of life. In close collaboration with patients, families, and the primary care team, PACT develops a quality of life care plan that optimizes pain and symptom management, advocates family and health care provider communication, and coordinates inpatient, outpatient, and home care. PACT clinicians also provide consultation in inpatient, outpatient, and home settings.

Our team is available by page 24 hours a day by calling the page operator at either Dana-Farber Cancer Institute 617-632-3352 or Boston Children’s Hospital 617-355-6363. When you call, ask for the PACT clinician on call.

New Patient Appointment Phone: 617-632-5042
Fax: 617-582-7271
Email: PactB@dfci.harvard.edu

Leadership – Pediatric Advanced Care Team (PACT)

Christina Ullrich, MD, MPH, Clinical Director, Pediatric Advanced Care Team
Psychosocial Care

Psychosocial care is an integral part of cancer treatment. When a child is diagnosed with cancer, the entire family is affected. Our multidisciplinary staff provides emotional support and a full range of psychosocial and behavioral consultation services not only to patients, but also to parents, siblings, the extended family and to schools and other community-based providers. Our comprehensive clinical care team helps patients and their families develop personalized treatment plans that optimize coping and help define treatment goals and concerns.

New Patient Appointment Phone: 617-632-6080

Leadership – Pediatric Psychosocial Oncology

Anna (Nina) C. Muriel, MD, MPH, Chief
Childhood Solid Tumor Center

Our Childhood Solid Tumor Center combines the expertise of clinicians at Dana-Farber and Boston Children’s Hospital to provide comprehensive care for children and teens with neuroblastoma, renal tumors, bone tumors, soft tissue sarcomas, liver and germ cell tumors, retinoblastoma, and a myriad of rare tumors including melanoma, carcinomas, and atypical tumors requiring extensive multidisciplinary expertise. We offer innovative treatment options and clinical trials, including novel experimental therapies for relapsed, recurrent, or refractory solid tumors, unmatched oncology-focused surgical care and interventional procedures, and pathology, molecular, and bench-driven translational research.

Patients receive care from a multidisciplinary team that includes pediatric oncologists, radiation oncologists, surgeons, pathologists, radiologists, nurses, fertility specialists, and psychosocial and physical therapy specialists.

In addition, we provide long-term treatment and childhood cancer survivor support through Dana-Farber’s David B. Perini Jr. Quality of Life Clinic and in-depth genetic counseling and surveillance support through the Pediatric Cancer Genetics Risk Program.

New Patient Appointment Phone: 617-632-5508 or 888-733-4662
Fax: 617-582-7434
Email: pedi_onc@dfci.harvard.edu

Leadership – Pediatric Solid Tumor Center

Allison O’Neill, MD, Clinical Director, Solid Tumor Center
Our Hematopoietic (Stem) Cell Transplant Program is one of the oldest and largest pediatric transplant centers in the nation. Focusing on the unique needs of children and adolescents, we provide comprehensive, in-depth care by teaming pediatric stem cell transplantation experts with pediatric medical experts from more than 30 subspecialty areas. Treatment advances from studies overseen at our center have led to international recognition of the program as one of the most accomplished pediatric transplant centers in the world.

Through internally initiated studies and affiliations with research organizations including the Children’s Oncology Group and the Blood and Marrow Clinical Trials Network, our program remains at the forefront of transplantation research and technology. This involvement provides our patients with access to the newest advances in radiology, oncology, and intensive care.

New Patient Appointment Phone: 617-632-3961 or 888-733-4662
Fax: 617-632-1990
Email: pedi_sct@dfci.harvard.edu

Leadership – Pediatric Stem Cell Transplant Center

Leslie S. Kean, MD, PhD, Director, Hematopoietic (Stem) Cell Transplant Program
Leslie Lehmann, MD, Clinical Director, Hematopoietic (Stem) Cell Transplant Program
Suneet Agarwal, MD, PhD, Co-Program Leader, Hematopoietic (Stem) Cell Transplant Program
Thankfully, the majority of children diagnosed with cancer today can expect to live long lives. Nevertheless, survivorship comes with numerous complexities including the enduring effects of treatment, the risk of second cancers, as well as social and psychological concerns. Dana-Farber/Boston Children’s Cancer and Blood Disorders Center addresses the long-term needs of survivors through two pediatric survivor clinics.

The David B. Perini Jr. Quality of Life Clinic, established in 1993 at Dana-Farber, provides multidisciplinary consultations to childhood cancer survivors of all ages. The Perini Clinic team works with patients to address issues they may face as a result of their cancer treatments, including cardiac issues, increased risk of second cancers, infertility, learning disabilities, impaired growth, and depression. Staff provide a comprehensive evaluation for each patient, along with an assessment of risks and potential late effects, and recommendations for follow-up care.

The Stop & Shop Family Pediatric Neuro-Oncology Outcomes Clinic addresses the long-term needs of pediatric brain tumor survivors, conducts research, and provides education for patients, families, and other health care community members. The clinic’s interdisciplinary team is staffed by pediatric brain tumor specialists and includes neuro-oncologists, neurologists, dermatologists, psychologists, neuropsychiatrists, and school resource liaisons. Understanding that pediatric brain tumor survivors are interested in improving their mental and physical health, socializing, developing relationships, and reaching goals in education and employment, the clinic also provides a wide range of educational resources and support services both on-site and out in the community.
Pediatric Cancer Survivorship (continued)

Referral Information
David B. Perini Jr. Quality of Life Clinic
Phone: 617-632-5124
Email: Perini_Clinic@dfci.harvard.edu

Stop & Shop Family Pediatric Neuro-Oncology Outcomes Clinic
Phone: 617-632-2680
Email: empowerclinic@dfci.harvard.edu
Fax: 617-632-2680

Leadership – Pediatric Cancer Survivorship
Lynda M. Vrooman, MD, MSc, Associate Medical Director, David B. Perini Jr. Quality of Life Clinic
Lisa R. Diller, MD, Medical Director, David B. Perini Jr. Quality of Life Clinic
Tab Cooney, MD, Director, Stop & Shop Pediatric Neuro-Oncology Outcomes Clinic